The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The optimization of induction chemotherapy for patients with AML
Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, discusses optimizing induction chemotherapy for acute myeloid leukemia (AML). Combining venetoclax with azacitidine (AZA+VEN) has shown effectiveness, despite lacking FDA approval. Trials incorporating anti-CD123 agents like tagraxofusp or pivekimab sunirine with AZA+VEN have improved measurable residual disease (MRD) negative rates and response duration. Another approach involves adding targeted agents for specific mutations, such as menin, FLT3, or IDH 1/2 inhibitors, to AZA+VEN. Longer randomized trials are needed to assess the impact on response depth and durability in chemotherapy-based treatments. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: AbbVie, Allogene, AstraZeneca, Genentech, Gilead, ImmunoGen, MEI Pharma, Precision, Rafael, Sanofi, Stemline; Advisory/Consulting: AbbVie, AstraZeneca, Auxenion, Bakx, Boehringer, Dark Blue Therapeutics, F. Hoffman La-Roche, Genentech, Gilead, Janssen, Legend, MEI Pharma, Redona, Sanofi, Sellas, Stemline, Vincerx; Stock options/Royalties: Reata Pharmaceutical (IP); Patent: Novartis, Eli Lilly, Reata Pharmaceutical.
